Neurology · Phase 2-3 · pulled 2026-11-06

Alzheimer's disease: trial sites and investigators

25 sites and 10 investigators from 300 completed and terminated Phase 2-3 trials of Alzheimer's disease (last 12 years), plus 209 trials recruiting now.

A cited data summary, not a recommendation to select or exclude any site. Every line links to the registry record behind it.

Sites

Sites are listed in the registry's own order: comparable trials listed (most first), ties by latest completion, then name. The Sitecite score is a second column. “Competing now” counts recruiting, active and not-yet-recruiting trials in the same indication at that site.

Alzheimer's disease: sites in the registry's trial-count order, with the Sitecite score as a second column
#	Site	Comparable trials listed	Trials (ClinicalTrials.gov)	Latest completion	Competing now	Score (0-100)
1	Brain Matters Research Delray Beach, United States · 6 spellings merged	48 25 completed, 23 terminated	NCT06881836 NCT06721156 NCT05463731 6 trials with titles NCT06881836 A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease completed 2026-09-01 NCT06721156 A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) terminated 2026-06-05 Stop reason on the record: “Termination Notes: Business reason” NCT05463731 A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1) completed 2026-05-12 NCT04619420 A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease terminated 2026-03-03 Stop reason on the record: “Posdinemab did not achieve statistical significance in slowing clinical decline” NCT04777396 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) completed 2026-01-30 NCT04777409 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) completed 2026-01-30	2026-09-01	12 NCT07589595 NCT06651567 NCT06540833 NCT06847321	83
2	JEM Research Institute Atlantis, United States · 8 spellings merged	39 19 completed, 20 terminated	NCT05463731 NCT06538116 NCT06304883 6 trials with titles NCT05463731 A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1) completed 2026-05-12 NCT06538116 A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease completed 2026-05-11 NCT06304883 Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects terminated 2026-03-11 Stop reason on the record: “Sponsor business decision” NCT04619420 A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease terminated 2026-03-03 Stop reason on the record: “Posdinemab did not achieve statistical significance in slowing clinical decline” NCT04777396 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) completed 2026-01-30 NCT04777409 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) completed 2026-01-30	2026-05-12	16 NCT07094516 NCT07589595 NCT06544616 NCT06976216	82
3	Advanced Memory Research Institute of New Jersey Toms River, United States · 12 spellings merged	37 17 completed, 20 terminated	NCT06881836 NCT05463731 NCT06538116 6 trials with titles NCT06881836 A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease completed 2026-09-01 NCT05463731 A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1) completed 2026-05-12 NCT06538116 A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease completed 2026-05-11 NCT04619420 A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease terminated 2026-03-03 Stop reason on the record: “Posdinemab did not achieve statistical significance in slowing clinical decline” NCT04777396 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) completed 2026-01-30 NCT04777409 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) completed 2026-01-30	2026-09-01	8 NCT06585787 NCT06976216 NCT05531526 NCT06653153	81
4	Banner Alzheimer's Institute Phoenix, United States · 7 spellings merged	30 15 completed, 15 terminated	NCT06881836 NCT06721156 NCT06538116 6 trials with titles NCT06881836 A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease completed 2026-09-01 NCT06721156 A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) terminated 2026-06-05 Stop reason on the record: “Termination Notes: Business reason” NCT06538116 A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease completed 2026-05-11 NCT04777396 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) completed 2026-01-30 NCT04777409 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) completed 2026-01-30 NCT05744401 A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease terminated 2025-02-05 Stop reason on the record: “Parent study failed to meet the primary endpoint and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints.”	2026-09-01	11 NCT07094516 NCT07602582 NCT06585787 NCT06957418	81
5	Toronto Memory Program Toronto, Canada · 7 spellings merged	30 14 completed, 16 terminated	NCT06721156 NCT06304883 NCT04619420 6 trials with titles NCT06721156 A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) terminated 2026-06-05 Stop reason on the record: “Termination Notes: Business reason” NCT06304883 Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects terminated 2026-03-11 Stop reason on the record: “Sponsor business decision” NCT04619420 A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease terminated 2026-03-03 Stop reason on the record: “Posdinemab did not achieve statistical significance in slowing clinical decline” NCT04777396 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) completed 2026-01-30 NCT04777409 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) completed 2026-01-30 NCT05891496 A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease completed 2025-09-08	2026-06-05	11 NCT07717411 NCT06976216 NCT07177352 NCT06653153	83
6	Pacific Research Network San Diego, United States · 11 spellings merged	30 16 completed, 14 terminated	NCT04619420 NCT05575076 NCT05026177 6 trials with titles NCT04619420 A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease terminated 2026-03-03 Stop reason on the record: “Posdinemab did not achieve statistical significance in slowing clinical decline” NCT05575076 Open-label Extension for Phase 3 Clinical Trials of Simufilam terminated 2025-01-31 Stop reason on the record: “sponsor decision” NCT05026177 Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease terminated 2024-12-30 Stop reason on the record: “Sponsor decision” NCT05267535 Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease terminated 2024-12-12 Stop reason on the record: “Treatment with 20 mg piromelatine did not demonstrate efficacy over treatment with placebo based on analysis with the ADAS-Cog 14 subscale and with other cognitive and neuropsychiatric parameters.” NCT02446132 Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type terminated 2024-09-06 Stop reason on the record: “The AVP-786 program was discontinued, the recruitment was stopped and all participants are no longer being examined or receiving intervention.” NCT04241068 A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 terminated 2024-07-22 Stop reason on the record: “Sponsor's Decision”	2026-03-03	2 NCT03887455 NCT04437511	86
7	Syrentis Clinical Research Santa Ana, United States · 4 spellings merged	30 16 completed, 14 terminated	NCT04619420 NCT04777396 NCT04777409 6 trials with titles NCT04619420 A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease terminated 2026-03-03 Stop reason on the record: “Posdinemab did not achieve statistical significance in slowing clinical decline” NCT04777396 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) completed 2026-01-30 NCT04777409 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) completed 2026-01-30 NCT02720445 Memory Improvement Through Nicotine Dosing (MIND) Study completed 2025-09-16 NCT05575076 Open-label Extension for Phase 3 Clinical Trials of Simufilam terminated 2025-01-31 Stop reason on the record: “sponsor decision” NCT05267535 Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease terminated 2024-12-12 Stop reason on the record: “Treatment with 20 mg piromelatine did not demonstrate efficacy over treatment with placebo based on analysis with the ADAS-Cog 14 subscale and with other cognitive and neuropsychiatric parameters.”	2026-03-03	12 NCT07717411 NCT07602582 NCT07033494 NCT07177352	87
8	Neuropsychiatric Research Center of Southwest Florida Fort Myers, United States · 8 spellings merged	28 14 completed, 14 terminated	NCT06721156 NCT05463731 NCT06538116 6 trials with titles NCT06721156 A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) terminated 2026-06-05 Stop reason on the record: “Termination Notes: Business reason” NCT05463731 A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1) completed 2026-05-12 NCT06538116 A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease completed 2026-05-11 NCT04619420 A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease terminated 2026-03-03 Stop reason on the record: “Posdinemab did not achieve statistical significance in slowing clinical decline” NCT05063539 A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease completed 2025-05-22 NCT05575076 Open-label Extension for Phase 3 Clinical Trials of Simufilam terminated 2025-01-31 Stop reason on the record: “sponsor decision”	2026-06-05	11 NCT07589595 NCT07033494 NCT06976203 NCT06847321	82
9	Bioclinica Research Orlando, United States · 12 spellings merged	27 15 completed, 12 terminated	NCT02446132 NCT03446001 NCT03486938 6 trials with titles NCT02446132 Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type terminated 2024-09-06 Stop reason on the record: “The AVP-786 program was discontinued, the recruitment was stopped and all participants are no longer being examined or receiving intervention.” NCT03446001 Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment completed 2023-04-04 NCT03486938 Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease completed 2022-11-02 NCT03823404 GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease completed 2022-01-01 NCT03518073 A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease completed 2021-10-25 NCT03367403 A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ) completed 2021-09-21	2024-09-06	0	84
10	Miami Jewish Health Systems Miami, United States · 9 spellings merged	25 16 completed, 9 terminated	NCT04619420 NCT06597058 NCT02720445 6 trials with titles NCT04619420 A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease terminated 2026-03-03 Stop reason on the record: “Posdinemab did not achieve statistical significance in slowing clinical decline” NCT06597058 Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill completed 2025-12-15 NCT02720445 Memory Improvement Through Nicotine Dosing (MIND) Study completed 2025-09-16 NCT05575076 Open-label Extension for Phase 3 Clinical Trials of Simufilam terminated 2025-01-31 Stop reason on the record: “sponsor decision” NCT05026177 Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease terminated 2024-12-30 Stop reason on the record: “Sponsor decision” NCT02446132 Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type terminated 2024-09-06 Stop reason on the record: “The AVP-786 program was discontinued, the recruitment was stopped and all participants are no longer being examined or receiving intervention.”	2026-03-03	12 NCT06651567 NCT07011745 NCT06052254 NCT05641688	87
11	Banner Sun Health Research Institute Sun City, United States · 5 spellings merged	24 10 completed, 14 terminated	NCT06881836 NCT06304883 NCT04777396 6 trials with titles NCT06881836 A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease completed 2026-09-01 NCT06304883 Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects terminated 2026-03-11 Stop reason on the record: “Sponsor business decision” NCT04777396 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) completed 2026-01-30 NCT04777409 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) completed 2026-01-30 NCT05891496 A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease completed 2025-09-08 NCT05575076 Open-label Extension for Phase 3 Clinical Trials of Simufilam terminated 2025-01-31 Stop reason on the record: “sponsor decision”	2026-09-01	11 NCT05641688 NCT07177352 NCT05531526 NCT03887455	77
12	Centrum Medyczne NeuroProtect Warsaw, Poland · 9 spellings merged	24 12 completed, 12 terminated	NCT06182085 NCT04777396 NCT04777409 6 trials with titles NCT06182085 Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD) completed 2026-07-02 NCT04777396 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) completed 2026-01-30 NCT04777409 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) completed 2026-01-30 NCT05063539 A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease completed 2025-05-22 NCT05189210 GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD) completed 2025-04-16 NCT05744401 A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease terminated 2025-02-05 Stop reason on the record: “Parent study failed to meet the primary endpoint and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints.”	2026-07-02	4 NCT07177352 NCT07170150 NCT05508789 NCT05399888	80
13	Hôpital La Grave Toulouse, France · 27 spellings merged	24 13 completed, 11 terminated	NCT04619420 NCT04777396 NCT04777409 6 trials with titles NCT04619420 A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease terminated 2026-03-03 Stop reason on the record: “Posdinemab did not achieve statistical significance in slowing clinical decline” NCT04777396 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) completed 2026-01-30 NCT04777409 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) completed 2026-01-30 NCT05189210 GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD) completed 2025-04-16 NCT05423522 Clinical Safety and Efficacy Evaluation of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's Disease completed 2024-10-29 NCT04592874 A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease completed 2024-09-12	2026-03-03	16 NCT06402838 NCT06159673 NCT06544616 NCT07011745	81
14	Summit Research Network Inc. Portland, United States · 11 spellings merged	23 8 completed, 15 terminated	NCT06721156 NCT04777396 NCT04777409 6 trials with titles NCT06721156 A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) terminated 2026-06-05 Stop reason on the record: “Termination Notes: Business reason” NCT04777396 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) completed 2026-01-30 NCT04777409 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) completed 2026-01-30 NCT05744401 A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease terminated 2025-02-05 Stop reason on the record: “Parent study failed to meet the primary endpoint and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints.” NCT05575076 Open-label Extension for Phase 3 Clinical Trials of Simufilam terminated 2025-01-31 Stop reason on the record: “sponsor decision” NCT04994483 Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease completed 2024-10-02	2026-06-05	6 NCT07688213 NCT07177352 NCT03887455 NCT07170150	78
15	Progressive Medical Research Port Orange, United States · 2 spellings merged	23 13 completed, 10 terminated	NCT05463731 NCT06538116 NCT06304883 6 trials with titles NCT05463731 A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1) completed 2026-05-12 NCT06538116 A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease completed 2026-05-11 NCT06304883 Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects terminated 2026-03-11 Stop reason on the record: “Sponsor business decision” NCT05744401 A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease terminated 2025-02-05 Stop reason on the record: “Parent study failed to meet the primary endpoint and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints.” NCT04994483 Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease completed 2024-10-02 NCT04592874 A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease completed 2024-09-12	2026-05-12	12 NCT07011732 NCT07602582 NCT06937229 NCT05531526	81
16	Ohio State University Columbus, United States · 9 spellings merged	22 11 completed, 11 terminated	NCT06881836 NCT04619420 NCT02720445 6 trials with titles NCT06881836 A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease completed 2026-09-01 NCT04619420 A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease terminated 2026-03-03 Stop reason on the record: “Posdinemab did not achieve statistical significance in slowing clinical decline” NCT02720445 Memory Improvement Through Nicotine Dosing (MIND) Study completed 2025-09-16 NCT05575076 Open-label Extension for Phase 3 Clinical Trials of Simufilam terminated 2025-01-31 Stop reason on the record: “sponsor decision” NCT05352763 Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease terminated 2024-12-31 Stop reason on the record: “Sponsor Decision” NCT05026177 Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease terminated 2024-12-30 Stop reason on the record: “Sponsor decision”	2026-09-01	12 NCT07094516 NCT06585787 NCT06976216 NCT07177352	85
17	Renstar Medical Research Ocala, United States · 2 spellings merged	22 8 completed, 14 terminated	NCT06881836 NCT05463731 NCT06538116 6 trials with titles NCT06881836 A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease completed 2026-09-01 NCT05463731 A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1) completed 2026-05-12 NCT06538116 A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease completed 2026-05-11 NCT04619420 A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease terminated 2026-03-03 Stop reason on the record: “Posdinemab did not achieve statistical significance in slowing clinical decline” NCT05063539 A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease completed 2025-05-22 NCT05575076 Open-label Extension for Phase 3 Clinical Trials of Simufilam terminated 2025-01-31 Stop reason on the record: “sponsor decision”	2026-09-01	14 NCT07717411 NCT07094516 NCT07589595 NCT06976216	81
18	Brain Research Center Amsterdam, Netherlands · 7 spellings merged	22 15 completed, 7 terminated	NCT06182085 NCT06721156 NCT04693520 6 trials with titles NCT06182085 Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD) completed 2026-07-02 NCT06721156 A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) terminated 2026-06-05 Stop reason on the record: “Termination Notes: Business reason” NCT04693520 Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease completed 2025-07-16 NCT05189210 GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD) completed 2025-04-16 NCT05323812 ASURE: Alzheimer Study Using oRal Edaravone completed 2024-12-30 NCT04592874 A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease completed 2024-09-12	2026-07-02	10 NCT07033494 NCT05531526 NCT06976203 NCT07170150	91
19	RE:Cognition Health London, United Kingdom · 15 spellings merged	21 9 completed, 12 terminated	NCT06304883 NCT05744401 NCT04592874 6 trials with titles NCT06304883 Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects terminated 2026-03-11 Stop reason on the record: “Sponsor business decision” NCT05744401 A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease terminated 2025-02-05 Stop reason on the record: “Parent study failed to meet the primary endpoint and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints.” NCT04592874 A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease completed 2024-09-12 NCT05310071 A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease terminated 2024-08-12 Stop reason on the record: “Sponsor's Decision” NCT04770220 An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects completed 2024-07-29 NCT04241068 A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 terminated 2024-07-22 Stop reason on the record: “Sponsor's Decision”	2026-03-11	12 NCT07717411 NCT06402838 NCT06544616 NCT03887455	77
20	The Memory Clinic Bennington, United States · 10 spellings merged	21 10 completed, 11 terminated	NCT04619420 NCT04777396 NCT04777409 6 trials with titles NCT04619420 A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease terminated 2026-03-03 Stop reason on the record: “Posdinemab did not achieve statistical significance in slowing clinical decline” NCT04777396 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) completed 2026-01-30 NCT04777409 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) completed 2026-01-30 NCT05063539 A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease completed 2025-05-22 NCT05026177 Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease terminated 2024-12-30 Stop reason on the record: “Sponsor decision” NCT02446132 Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type terminated 2024-09-06 Stop reason on the record: “The AVP-786 program was discontinued, the recruitment was stopped and all participants are no longer being examined or receiving intervention.”	2026-03-03	7 NCT07011732 NCT07284472 NCT06544616 NCT03887455	79
21	Premiere Research Institute West Palm Beach, United States · 11 spellings merged	20 9 completed, 11 terminated	NCT05463731 NCT06538116 NCT06304883 6 trials with titles NCT05463731 A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1) completed 2026-05-12 NCT06538116 A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease completed 2026-05-11 NCT06304883 Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects terminated 2026-03-11 Stop reason on the record: “Sponsor business decision” NCT04619420 A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease terminated 2026-03-03 Stop reason on the record: “Posdinemab did not achieve statistical significance in slowing clinical decline” NCT05189210 GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD) completed 2025-04-16 NCT05575076 Open-label Extension for Phase 3 Clinical Trials of Simufilam terminated 2025-01-31 Stop reason on the record: “sponsor decision”	2026-05-12	9 NCT07589595 NCT06544616 NCT06651567 NCT06585787	80
22	Centricity Research Halifax, Canada · 13 spellings merged	20 8 completed, 12 terminated	NCT06304883 NCT04777396 NCT04777409 6 trials with titles NCT06304883 Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects terminated 2026-03-11 Stop reason on the record: “Sponsor business decision” NCT04777396 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) completed 2026-01-30 NCT04777409 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) completed 2026-01-30 NCT05026177 Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease terminated 2024-12-30 Stop reason on the record: “Sponsor decision” NCT04592874 A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease completed 2024-09-12 NCT05310071 A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease terminated 2024-08-12 Stop reason on the record: “Sponsor's Decision”	2026-03-11	6 NCT06976216 NCT07177352 NCT05531526 NCT03887455	75
23	Hospital de la Santa Creu i Sant Pau Barcelona, Spain · 11 spellings merged	19 10 completed, 9 terminated	NCT06721156 NCT04777396 NCT04777409 6 trials with titles NCT06721156 A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) terminated 2026-06-05 Stop reason on the record: “Termination Notes: Business reason” NCT04777396 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) completed 2026-01-30 NCT04777409 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) completed 2026-01-30 NCT05744401 A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease terminated 2025-02-05 Stop reason on the record: “Parent study failed to meet the primary endpoint and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints.” NCT04592874 A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease completed 2024-09-12 NCT05310071 A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease terminated 2024-08-12 Stop reason on the record: “Sponsor's Decision”	2026-06-05	7 NCT07177352 NCT06653153 NCT07170150 NCT05508789	83
24	University of Rochester Medical Center Rochester, United States · 7 spellings merged	19 8 completed, 11 terminated	NCT06304883 NCT06630390 NCT05575076 6 trials with titles NCT06304883 Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects terminated 2026-03-11 Stop reason on the record: “Sponsor business decision” NCT06630390 Daridorexant to Prevent Delirium After Heart Surgery completed 2025-02-16 NCT05575076 Open-label Extension for Phase 3 Clinical Trials of Simufilam terminated 2025-01-31 Stop reason on the record: “sponsor decision” NCT04886063 Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease terminated 2024-10-23 Stop reason on the record: “ATH-1017-AD-0203 was terminated after the Ph2/3 parent trial (LIFT-AD; NCT04488419) did not meet its primary endpoint, the GST score.” NCT04994483 Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease completed 2024-10-02 NCT04592874 A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease completed 2024-09-12	2026-03-11	8 NCT07177352 NCT03887455 NCT07170150 NCT04437511	85
25	Emory University Atlanta, United States · 12 spellings merged	19 8 completed, 11 terminated	NCT04619420 NCT04592874 NCT03919162 6 trials with titles NCT04619420 A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease terminated 2026-03-03 Stop reason on the record: “Posdinemab did not achieve statistical significance in slowing clinical decline” NCT04592874 A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease completed 2024-09-12 NCT03919162 A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD terminated 2024-08-12 Stop reason on the record: “It has been made the strategic decision to terminate the study. This decision to terminate the study early is not being made for safety reasons.” NCT04241068 A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 terminated 2024-07-22 Stop reason on the record: “Sponsor's Decision” NCT06424236 Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation terminated 2023-11-13 Stop reason on the record: “DIAN-TU announced the discontinuation of the DIAN-TU-001 OLE based on the status of the drug program and findings from an interim efficacy analysis and.” NCT03860935 Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy completed 2023-05-11	2026-03-03	10 NCT05741060 NCT03887455 NCT06223360 NCT04098666	85

Investigators

Principal investigators and study chairs of the comparable trials, most trials first. Papers are matched on name, affiliation and condition; the match confidence is shown on each.

Alzheimer's disease: principal investigators and study chairs of the comparable trials, with matched papers
#	Investigator	Comparable trials	Trials (ClinicalTrials.gov)	Papers (PubMed)
1	Philip Scheltens Amsterdam UMC Alzheimer Center de Boelelaan Amsterdam The Netherlands	3	NCT04445831 NCT02423122 NCT02389413	PMID 42785112 The journal of prevention of Alzheimer's disease, 2026 · High match PMID 42527300 eNeuro, 2026 · High match PMID 42516031 Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026 · Medium match
2	Patrick Lao Columbia University	3	NCT03744312 NCT03373604 NCT02831283	PMID 42449194 Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026 · High match PMID 41736285 Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026 · High match PMID 41208739 Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025 · High match
3	Gene Alexander University of Arizona	2	NCT04018092 NCT02292238	PMID 38798660 Research square, 2025 · High match
4	Jacobo Mintzer Ralph H. Johnson Veterans Affairs Medical Center (VAMC)	2	NCT05644262 NCT02346201	PMID 42178577 Alzheimer's research & therapy, 2026 · High match PMID 41521126 International psychogeriatrics, 2026 · High match PMID 41250235 Alzheimer's research & therapy, 2025 · High match
5	James Kupiec Cassava Sciences	2	NCT05026177 NCT04994483	No paper matched at High or Medium confidence
6	Lon Schneider Keck School of Medicine of USC, Los Angeles, CA	2	NCT05267535 NCT02615002	PMID 41722578 The Lancet. Neurology, 2026 · High match PMID 40243238 Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026 · High match PMID 39498781 The Cochrane database of systematic reviews, 2024 · High match
7	Howard Feldman Alzheimer's Disease Cooperative Study (ADCS)	2	NCT03919162 NCT03710642	PMID 40528300 Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025 · High match PMID 39636028 Journal of Alzheimer's disease : JAD, 2024 · Medium match
8	Rong Zhang University of Texas Southwestern Medical Center and Texas Health Resources	2	NCT03354143 NCT02913664	PMID 42951976 Nature, 2026 · High match
9	Steven Arnold Massachusetts General Hospital	2	NCT05004688 NCT04507126	PMID 41697669 JAMA neurology, 2026 · High match PMID 41505204 Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026 · High match PMID 41137616 Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025 · High match
10	Daniel Taylor The University of Arizona	2	NCT05015803 NCT04018092	No paper matched at High or Medium confidence

How to read this

Sites are counted from the facility lists on the registry record, with spelling variants merged. “Listed on the trial” means the registry shows the site as a location; it is not a count of patients enrolled. The method, the formula and the published tests.

Want this for your own protocol or your CRO's list?

Leave your indication and the CRO's names. We reply by email with each one checked against these records.